[Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].

Abstract

Naftopidil was administered to 67 patients with benign prostatic hyperplasia (BPH) for 12 months. Changes in total/each International Prostate Symptom Score (IPSS) for irritative and obstructive symptoms, nocturia, and residual urine volume were compared before and after its administration. As a result, a significant decrease of score was found in total-IPSS, obstructive and irritative symptoms, which also showed a tendency to decrease at the end of the first month. Nocturia and residual urine volume also significantly decreased after its administration. Naftopidil is considered to be effective in the treatment of BPH, especially irritative symptoms including nocturia in treatments for BPH, because both irritative and obstructive symptoms (IPSS subjective endpoints) and residual urine volume (objective endpoint) were improved after its long-term administration.

• Authors: Toshiyuki Akasaka, Hiroyoshi Funaki, Shigeru Hirano, Mitsuru Ohinata, Mikihiko Fujishima, Takuji Kudou, Akira Suzuki, Masahiro Iinuma
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 49 Issue 4 Pg. 189-93 (Apr 2003) ISSN: 0018-1994 [Print] Japan
• PMID: 12784711 (Publication Type: English Abstract, Journal Article)

Chemical References

• Adrenergic alpha-Antagonists
• Naphthalenes
• Piperazines
• naftopidil

Topics

• Adrenergic alpha-Antagonists (administration & dosage, pharmacology)
• Aged
• Aged, 80 and over
• Drug Administration Schedule
• Humans
• Male
• Middle Aged
• Naphthalenes (administration & dosage, pharmacology)
• Piperazines (administration & dosage, pharmacology)
• Prostatic Hyperplasia (complications)
• Quality of Life
• Urination Disorders (drug therapy, etiology)
• Urodynamics (drug effects)